#TEK TekCapital PLC – Placing to raise £2.25 Million(C.US$2.7M)
Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products that can improve people’s lives announces that it has raised a total of £2.25 million (c.US$2.7m) before expenses, in an oversubscribed placing from existing and new shareholders, by way of the issue of, in aggregate, 14,062,500 new ordinary shares of 0.4 […]
#TYM Tertiary Minerals PLC – Placing to raise £300,000
Tertiary Minerals plc (AIM: TYM), the London listed explorer focussed on energy transition and precious metals in Zambia and Nevada, USA, is pleased to announce it has raised £300,000 before expenses through a placing of 250,000,000 new ordinary shares of 0.01 pence each (the “Placing Shares”) and 125,000,000 attached warrants (the “Placing Warrants”) in the […]
#BRES Blencowe Resources PLC – Final Metallurgical Testing Programs
Commencement of Final Metallurgical Testing Programs for Orom-Cross Graphite Project as samples sent to both China and USA. Highlights · 20kgs of concentrate sent by air to technical experts Wuhan University of Technology (“WUT”) in China to begin final metallurgical test procedure. · This concentrate is the end product recently produced by IMO in Perth, […]
#SVML Sovereign Metals Ltd – Issue of Unlisted Performance Rights
Sovereign Metals Limited (Sovereign or the Company) (ASX:SVM, AIM:SVML) advises that it has issued 1,560,000 Performance Rights to key employees and consultants as follows: · 740,000 performance rights subject to the “Pre-Feasibility Study Milestone” expiring on 30 September 2023; and · 820,000 performance rights subject to the “Feasibility Study Mine Milestone” expiring on 31 October […]
#FCM First Class Metals PLC – Exercise of Warrants and Issue of Equity
First Class Metals PLC (LSE:FCM) announces that it has received several notices to exercise warrants over a total of 450,582 Ordinary Shares (the “Warrant Shares“), for which funds of GBP 46,683.20 have been received by the Company. Application will be made to the Financial Conduct Authority (“FCA”) for admission of the above Ordinary Shares to […]
#ECHO Echo Energy PLC – Debt Restructuring Completion & Issue of Equity
Echo Energy plc, the Latin American focused energy company, announces that in respect of completion of the restructuring of the Company’s Luxembourg listed EUR 20.0m 8.0% secured notes (the “Notes”) and the Company’s 5.0 million 8.0% secured convertible debt facility (the “Facility”), it has today made application for 3,570,766,386 new ordinary shares in the Company […]
Power Metals Resources #POW – Kalahari Key Acquisition Complete – Power Metal Now Holds 87.71% Interest. Molopo Farms Drilling Update
Power Metal Resources PLC (LON:POW), the London listed exploration company seeking large-scale metal discoveries across its global project portfolio announces the completion of the transaction to increase the Company’s interest in Kalahari Key Mineral Exploration Pty Limited (“KKME” or “Kalahari Key”) further details of which were provided in the Company’s announcement of 3 November 2022 […]
#KAV Kavango Resources Plc – Publication of Prospectus
Further to the announcement of 24 October 2022 in which Kavango announced it had conditionally raised £3,000,000 before expenses by the issue of 166,666,660 new ordinary shares of £0.001 each in the capital of the Company (the “New Ordinary Shares”) at a price per share of 1.8 pence, the Company is pleased to announce that […]
#SVML Sovereign Metals Limited- Result of AGM
The Annual General Meeting (AGM) of Sovereign Metals Limited (Company) (ASX:SVM, AIM:SVML) was held today, 18 November 2022, at 10.00am (AWST). The resolutions voted on were in accordance with the Notice of AGM previously advised to the Australian Securities Exchange and shareholders. All resolutions were decided on and carried by way of poll. In accordance […]
#HVO hVIVO plc – Investors’ Chronicle
Building on decades of experience, hVIVO is currently the only CRO focused on challenge studies, providing world class expertise and capabilities in challenge agent manufacture, a unique portfolio of established human challenge models to test a broad range of infectious and respiratory disease products, and specialist drug development and clinical consultancy services through its Venn Life Sciences subsidiary. hVIVO contract awards Since the release of interim results in early September, hVIVO has announced a massive £13.4mn contract with a US biotechnology client, a repeat customer, to test its respiratory syncytial virus antiviral candidate using hVIVO’s established RSV Human Challenge Study Model. Although difficult to assess the challenge study market, Liberum Capital estimates there are around 20 challenge studies conducted each year. Using the prevailing average contract size of £6.7mn, this indicates £100mn-£135mn of challenge study work each year, excluding any additional income through manufacturing and validating bespoke challenge agent. Around 60 per cent of hVIVO’s current order book relates to biotech customers and the balance relates to big pharma, with the group carrying out three active challenge studies for big pharma in the first half of 2022 and two full-service challenge studies with values exceeding £25mn. Moreover, hVIVO has signed up eight challenge studies with big pharma companies since 2018, 12 and all the big pharma clients are repeat customers. Improving financials Backed by a bumper order book and having booked £9mn of group revenue in July and August 2022, house broker FinnCap expects the group’s hVIVO division, which carries out the challenge studies, to grow revenue from £29.4mn last year to £42.5mn in 2022 and account for 82 per cent of its total revenue estimate of £51.1mn. Furthermore, taking account of challenge study contract wins, revenue from Venn Life, laboratory services and non-challenge studies, the brokerage estimates that £53mn of its 2023 revenue estimate of £56mn is already covered. SGS’s expertise is in performing influenza challenge studies, but it also has Malaria challenge, and RSV challenge models.